BIOMIND LABS INC. Cash Flow Conversion Efficiency
BIOMIND LABS INC. cash flow conversion efficiency. Based on the latest financial reports, BIOMIND LABS INC. (3XI) has a cash flow conversion efficiency ratio of 0.025x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-38.70K ≈ $-45.24K USD) by net assets (€-1.56 Million ≈ $-1.82 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of BIOMIND LABS INC. (2021–2024)
Cash flow conversion efficiency of BIOMIND LABS INC. from 2021 to 2024. This chart illustrates how BIOMIND LABS INC.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View BIOMIND LABS INC. stock quote for real-time trading data and today's change.
BIOMIND LABS INC. Cash Flow Conversion Ratio Explained
BIOMIND LABS INC. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
BIOMIND LABS INC. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BIOMIND LABS INC. ranked by their cash flow conversion efficiency. Also see market value of BIOMIND LABS INC. for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Axilion Smart Mobility Ltd
TA:AILN
|
-0.914x |
|
Whitemud Resources Inc
V:WMK
|
0.164x |
|
Future PLC
LSE:FUTR
|
0.068x |
|
Pembroke VCT PLC
LSE:PEMB
|
-0.009x |
|
N2OFF Inc
NASDAQ:NITO
|
-0.089x |
|
Coloseum Holding a.s.
PR:COLOS
|
N/A |
|
XTL Biopharmaceuticals Ltd
TA:XTLB
|
-0.055x |
|
60 Degrees Pharmaceuticals, Inc. Common Stock
NASDAQ:SXTP
|
-0.883x |
Annual Cash Flow Conversion Efficiency for BIOMIND LABS INC. (2021–2024)
The table below shows the annual cash flow conversion efficiency of BIOMIND LABS INC. from 2021 to 2024. Review BIOMIND LABS INC. free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €-1.30 Million ≈ $-1.52 Million |
€-354.43K ≈ $-414.36K |
0.273x | -49.03% |
| 2023-12-31 | €-1.43 Million ≈ $-1.67 Million |
€-765.93K ≈ $-895.45K |
0.535x | -93.84% |
| 2022-12-31 | €-247.66K ≈ $-289.54K |
€-2.15 Million ≈ $-2.51 Million |
8.685x | +997.29% |
| 2021-12-31 | €2.19 Million ≈ $2.56 Million |
€-2.12 Million ≈ $-2.48 Million |
-0.968x | -- |
About BIOMIND LABS INC.
Biomind Labs Inc., a biotech research and development company, focuses on developing novel pharmaceutical drugs and nanotech delivery systems for various psychiatric and neurological conditions. The company is developing BMND01, which is in Phase II clinical trials for use in the treatment of depression; BMND08, a 5-Metoxi-N,N-dimethyltryptamine based formulation that is in Phase II clinical tria… Read more